Hellingman Daan, Wan Oi Yan, de Wit-van der Veen Berlinda J, van der Ploeg Iris M, Elkhuizen Paula H M, Rutgers Emiel J Th, Stokkel Marcel P M
Departments of Nuclear Medicine.
Surgical Oncology.
Nucl Med Commun. 2019 Apr;40(4):317-324. doi: 10.1097/MNM.0000000000000971.
Lymphoscintigraphy is considered a useful tool to optimize sentinel lymph node (SLN) identification. Nonvisualization of the SLN is associated with a lower SLN identification rate. The aim of this study was to identify preoperative factors associated with SLN nonvisualization on lymphoscintigraphy.
A total of 2050 consecutive SLN procedures were evaluated from clinically node-negative breast cancer patients. Planar lymphoscintigraphy was performed at 3 h after an intratumoral injection of technetium-99m-nanocolloid. This technique was used for extra-axillary SLN identification. Patient, tumor, and treatment characteristics were analyzed for association with SLN nonvisualization. Factors with a P-value less than 0.1 in univariate analysis were included in a multivariate logistic regression model.
The SLN visualization rate was 86.7%. In multivariate logistic regression, age of at least 70 years [odds ratio (OR): 3.24; 95% confidence interval (CI): 2.14-4.91)], BMI of at least 30 (OR: 1.93; 95% CI: 1.39-2.69), T3/T4-tumors (OR: 2.70; 95% CI: 1.37-5.32), medially/centrally located tumors (OR: 1.52; 95% CI: 1.17-1.99), previous mantle field radiation (OR: 4.04; 95% CI: 1.74-9.35), nonpalpable tumors (OR: 1.88; 95% CI: 1.36-2.60), and presence of iodine seeds (OR: 1.35; 95% CI: 1.02-1.78) were associated significantly with nonvisualization on lymphoscintigraphy. Nonvisualization was the strongest independent predictor of unsuccessful intraoperative SLN identification (P<0.001). Overall, the SLN identification rate was 97.7% because of the use of additional imaging and blue dye.
This study reports new tumor and treatment-related risk factors for nonvisualization on lymphoscintigraphy by using an intratumoral injection in primary breast cancer. We recommend a periareolar subcutaneous injection to improve SLN visualization in patients with limited prognostic and therapeutic relevance of internal mammary chain SLN identification.
淋巴闪烁显像被认为是优化前哨淋巴结(SLN)识别的有用工具。SLN未显影与较低的SLN识别率相关。本研究的目的是确定淋巴闪烁显像中与SLN未显影相关的术前因素。
对连续2050例临床腋窝淋巴结阴性的乳腺癌患者的SLN手术进行评估。在瘤内注射99m锝纳米胶体后3小时进行平面淋巴闪烁显像。该技术用于腋窝外SLN识别。分析患者、肿瘤和治疗特征与SLN未显影的相关性。单因素分析中P值小于0.1的因素纳入多因素逻辑回归模型。
SLN显影率为86.7%。在多因素逻辑回归中,年龄至少70岁[比值比(OR):3.24;95%置信区间(CI):2.14 - 4.91]、体重指数至少30(OR:1.93;95% CI:1.39 - 2.69)、T3/T4期肿瘤(OR:2.70;95% CI:1.37 - 5.32)、肿瘤位于内侧/中央(OR:1.52;95% CI:1.17 - 1.99)、既往有斗篷野放疗史(OR:4.04;95% CI:1.74 - 9.35)、不可触及的肿瘤(OR:1.88;95% CI:1.36 - 2.60)以及存在碘籽源(OR:1.35;95% CI:1.02 - 1.78)与淋巴闪烁显像未显影显著相关。未显影是术中SLN识别失败的最强独立预测因素(P<0.001)。总体而言,由于使用了额外的成像和蓝色染料,SLN识别率为97.7%。
本研究报告了通过在原发性乳腺癌中进行瘤内注射,淋巴闪烁显像未显影的新的肿瘤和治疗相关风险因素。对于内乳链SLN识别预后和治疗相关性有限的患者,我们建议采用乳晕周围皮下注射以改善SLN显影。